nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—breast cancer	0.378	0.829	CbGaD
Pimecrolimus—CYP3A4—breast cancer	0.0781	0.171	CbGaD
Pimecrolimus—CYP3A4—Exemestane—breast cancer	0.0325	0.133	CbGbCtD
Pimecrolimus—CYP3A4—Letrozole—breast cancer	0.0277	0.113	CbGbCtD
Pimecrolimus—CYP3A4—Anastrozole—breast cancer	0.0247	0.101	CbGbCtD
Pimecrolimus—CYP3A4—Toremifene—breast cancer	0.0226	0.0921	CbGbCtD
Pimecrolimus—CYP3A4—Fulvestrant—breast cancer	0.021	0.0856	CbGbCtD
Pimecrolimus—CYP3A4—Thiotepa—breast cancer	0.0187	0.0763	CbGbCtD
Pimecrolimus—CYP3A4—Ixabepilone—breast cancer	0.0171	0.0698	CbGbCtD
Pimecrolimus—CYP3A4—Lapatinib—breast cancer	0.0165	0.0672	CbGbCtD
Pimecrolimus—CYP3A4—Raloxifene—breast cancer	0.0125	0.0509	CbGbCtD
Pimecrolimus—CYP3A4—Vinorelbine—breast cancer	0.00913	0.0373	CbGbCtD
Pimecrolimus—CYP3A4—Tamoxifen—breast cancer	0.00824	0.0336	CbGbCtD
Pimecrolimus—CYP3A4—Mitoxantrone—breast cancer	0.00804	0.0328	CbGbCtD
Pimecrolimus—CYP3A4—Paclitaxel—breast cancer	0.00641	0.0262	CbGbCtD
Pimecrolimus—CYP3A4—Irinotecan—breast cancer	0.00633	0.0258	CbGbCtD
Pimecrolimus—CYP3A4—Vinblastine—breast cancer	0.00562	0.023	CbGbCtD
Pimecrolimus—CYP3A4—Docetaxel—breast cancer	0.00464	0.0189	CbGbCtD
Pimecrolimus—CYP3A4—Doxorubicin—breast cancer	0.00346	0.0141	CbGbCtD
Pimecrolimus—MTOR—mammary gland—breast cancer	0.00273	0.0753	CbGeAlD
Pimecrolimus—FKBP1A—mammary gland—breast cancer	0.00245	0.0677	CbGeAlD
Pimecrolimus—FKBP1A—nipple—breast cancer	0.00203	0.056	CbGeAlD
Pimecrolimus—MTOR—embryo—breast cancer	0.00186	0.0514	CbGeAlD
Pimecrolimus—MTOR—epithelium—breast cancer	0.00152	0.0419	CbGeAlD
Pimecrolimus—MTOR—skin of body—breast cancer	0.00145	0.0399	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—breast cancer	0.00137	0.0377	CbGeAlD
Pimecrolimus—MTOR—endometrium—breast cancer	0.00136	0.0376	CbGeAlD
Pimecrolimus—FKBP1A—skin of body—breast cancer	0.0013	0.0359	CbGeAlD
Pimecrolimus—MTOR—uterus—breast cancer	0.00126	0.0346	CbGeAlD
Pimecrolimus—MTOR—pituitary gland—breast cancer	0.00123	0.034	CbGeAlD
Pimecrolimus—MTOR—adipose tissue—breast cancer	0.00123	0.0339	CbGeAlD
Pimecrolimus—FKBP1A—endometrium—breast cancer	0.00123	0.0338	CbGeAlD
Pimecrolimus—FKBP1A—uterus—breast cancer	0.00113	0.0312	CbGeAlD
Pimecrolimus—MTOR—female reproductive system—breast cancer	0.00113	0.0311	CbGeAlD
Pimecrolimus—FKBP1A—pituitary gland—breast cancer	0.00111	0.0306	CbGeAlD
Pimecrolimus—FKBP1A—adipose tissue—breast cancer	0.0011	0.0305	CbGeAlD
Pimecrolimus—MTOR—adrenal gland—breast cancer	0.0011	0.0304	CbGeAlD
Pimecrolimus—MTOR—bone marrow—breast cancer	0.00107	0.0294	CbGeAlD
Pimecrolimus—MTOR—female gonad—breast cancer	0.00103	0.0283	CbGeAlD
Pimecrolimus—FKBP1A—female reproductive system—breast cancer	0.00102	0.028	CbGeAlD
Pimecrolimus—FKBP1A—adrenal gland—breast cancer	0.000991	0.0273	CbGeAlD
Pimecrolimus—Everolimus—MTOR—breast cancer	0.000986	0.217	CrCbGaD
Pimecrolimus—FKBP1A—bone marrow—breast cancer	0.000959	0.0264	CbGeAlD
Pimecrolimus—MTOR—endocrine gland—breast cancer	0.000955	0.0264	CbGeAlD
Pimecrolimus—FKBP1A—female gonad—breast cancer	0.000924	0.0255	CbGeAlD
Pimecrolimus—FKBP1A—endocrine gland—breast cancer	0.000859	0.0237	CbGeAlD
Pimecrolimus—Temsirolimus—MTOR—breast cancer	0.000666	0.146	CrCbGaD
Pimecrolimus—MTOR—lymph node—breast cancer	0.00066	0.0182	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—breast cancer	0.000594	0.0164	CbGeAlD
Pimecrolimus—Sirolimus—MTOR—breast cancer	0.000587	0.129	CrCbGaD
Pimecrolimus—Tacrolimus—MTOR—breast cancer	0.000587	0.129	CrCbGaD
Pimecrolimus—Sirolimus—SLCO1B1—breast cancer	0.000557	0.122	CrCbGaD
Pimecrolimus—CYP3A4—female reproductive system—breast cancer	0.000332	0.00915	CbGeAlD
Pimecrolimus—CYP3A4—endocrine gland—breast cancer	0.000281	0.00775	CbGeAlD
Pimecrolimus—Everolimus—CYP3A4—breast cancer	0.000204	0.0448	CrCbGaD
Pimecrolimus—Temsirolimus—CYP2D6—breast cancer	0.00016	0.0353	CrCbGaD
Pimecrolimus—Temsirolimus—CYP3A4—breast cancer	0.000138	0.0302	CrCbGaD
Pimecrolimus—Tacrolimus—CYP3A4—breast cancer	0.000121	0.0266	CrCbGaD
Pimecrolimus—Sirolimus—CYP3A4—breast cancer	0.000121	0.0266	CrCbGaD
Pimecrolimus—Temsirolimus—ABCB1—breast cancer	0.000115	0.0252	CrCbGaD
Pimecrolimus—Tacrolimus—ALB—breast cancer	0.000106	0.0232	CrCbGaD
Pimecrolimus—Tacrolimus—ABCB1—breast cancer	0.000101	0.0222	CrCbGaD
Pimecrolimus—Sirolimus—ABCB1—breast cancer	0.000101	0.0222	CrCbGaD
Pimecrolimus—Nausea—Goserelin—breast cancer	5.57e-05	0.000414	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—breast cancer	5.55e-05	0.000412	CcSEcCtD
Pimecrolimus—Nervous system disorder—Paclitaxel—breast cancer	5.54e-05	0.000412	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—breast cancer	5.54e-05	0.000411	CcSEcCtD
Pimecrolimus—Urticaria—Mitoxantrone—breast cancer	5.5e-05	0.000409	CcSEcCtD
Pimecrolimus—Back pain—Capecitabine—breast cancer	5.49e-05	0.000408	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—breast cancer	5.49e-05	0.000408	CcSEcCtD
Pimecrolimus—Diarrhoea—Thiotepa—breast cancer	5.48e-05	0.000408	CcSEcCtD
Pimecrolimus—Skin disorder—Paclitaxel—breast cancer	5.48e-05	0.000408	CcSEcCtD
Pimecrolimus—Body temperature increased—Irinotecan—breast cancer	5.47e-05	0.000407	CcSEcCtD
Pimecrolimus—Abdominal pain—Irinotecan—breast cancer	5.47e-05	0.000407	CcSEcCtD
Pimecrolimus—Body temperature increased—Mitoxantrone—breast cancer	5.47e-05	0.000407	CcSEcCtD
Pimecrolimus—Abdominal pain—Mitoxantrone—breast cancer	5.47e-05	0.000407	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—breast cancer	5.46e-05	0.000406	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—breast cancer	5.44e-05	0.000404	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—breast cancer	5.43e-05	0.000404	CcSEcCtD
Pimecrolimus—Infestation NOS—Methotrexate—breast cancer	5.41e-05	0.000402	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—breast cancer	5.41e-05	0.000402	CcSEcCtD
Pimecrolimus—Vomiting—Vinorelbine—breast cancer	5.34e-05	0.000397	CcSEcCtD
Pimecrolimus—Body temperature increased—Gemcitabine—breast cancer	5.33e-05	0.000396	CcSEcCtD
Pimecrolimus—Rash—Vinorelbine—breast cancer	5.29e-05	0.000393	CcSEcCtD
Pimecrolimus—Dermatitis—Vinorelbine—breast cancer	5.29e-05	0.000393	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—breast cancer	5.27e-05	0.000392	CcSEcCtD
Pimecrolimus—Urticaria—Fluorouracil—breast cancer	5.27e-05	0.000391	CcSEcCtD
Pimecrolimus—Headache—Vinorelbine—breast cancer	5.26e-05	0.000391	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—breast cancer	5.26e-05	0.000391	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—breast cancer	5.25e-05	0.00039	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—breast cancer	5.25e-05	0.00039	CcSEcCtD
Pimecrolimus—Body temperature increased—Fluorouracil—breast cancer	5.24e-05	0.00039	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—breast cancer	5.18e-05	0.000385	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Paclitaxel—breast cancer	5.14e-05	0.000382	CcSEcCtD
Pimecrolimus—Cough—Docetaxel—breast cancer	5.12e-05	0.00038	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—breast cancer	5.1e-05	0.000379	CcSEcCtD
Pimecrolimus—Hypersensitivity—Mitoxantrone—breast cancer	5.1e-05	0.000379	CcSEcCtD
Pimecrolimus—Hypersensitivity—Irinotecan—breast cancer	5.1e-05	0.000379	CcSEcCtD
Pimecrolimus—Vomiting—Thiotepa—breast cancer	5.1e-05	0.000379	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—breast cancer	5.09e-05	0.000378	CcSEcCtD
Pimecrolimus—Paraesthesia—Paclitaxel—breast cancer	5.07e-05	0.000377	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—breast cancer	5.06e-05	0.000376	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—breast cancer	5.06e-05	0.000376	CcSEcCtD
Pimecrolimus—Rash—Thiotepa—breast cancer	5.05e-05	0.000376	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—breast cancer	5.05e-05	0.000375	CcSEcCtD
Pimecrolimus—Dermatitis—Thiotepa—breast cancer	5.05e-05	0.000375	CcSEcCtD
Pimecrolimus—Dyspnoea—Paclitaxel—breast cancer	5.03e-05	0.000374	CcSEcCtD
Pimecrolimus—Headache—Thiotepa—breast cancer	5.02e-05	0.000373	CcSEcCtD
Pimecrolimus—Arthralgia—Docetaxel—breast cancer	4.99e-05	0.000371	CcSEcCtD
Pimecrolimus—Nausea—Vinorelbine—breast cancer	4.99e-05	0.000371	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	4.96e-05	0.000368	CcSEcCtD
Pimecrolimus—Cough—Capecitabine—breast cancer	4.95e-05	0.000368	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—breast cancer	4.92e-05	0.000366	CcSEcCtD
Pimecrolimus—Hypersensitivity—Fluorouracil—breast cancer	4.88e-05	0.000363	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—breast cancer	4.88e-05	0.000363	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Paclitaxel—breast cancer	4.87e-05	0.000362	CcSEcCtD
Pimecrolimus—Arthralgia—Capecitabine—breast cancer	4.83e-05	0.000359	CcSEcCtD
Pimecrolimus—Pain—Paclitaxel—breast cancer	4.83e-05	0.000359	CcSEcCtD
Pimecrolimus—Constipation—Paclitaxel—breast cancer	4.83e-05	0.000359	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—breast cancer	4.82e-05	0.000358	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	4.8e-05	0.000357	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—breast cancer	4.79e-05	0.000356	CcSEcCtD
Pimecrolimus—Oedema—Docetaxel—breast cancer	4.78e-05	0.000356	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Docetaxel—breast cancer	4.78e-05	0.000356	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—breast cancer	4.77e-05	0.000355	CcSEcCtD
Pimecrolimus—Pruritus—Gemcitabine—breast cancer	4.77e-05	0.000355	CcSEcCtD
Pimecrolimus—Nausea—Thiotepa—breast cancer	4.76e-05	0.000354	CcSEcCtD
Pimecrolimus—Infection—Docetaxel—breast cancer	4.75e-05	0.000353	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—breast cancer	4.75e-05	0.000353	CcSEcCtD
Pimecrolimus—Diarrhoea—Irinotecan—breast cancer	4.74e-05	0.000352	CcSEcCtD
Pimecrolimus—Diarrhoea—Mitoxantrone—breast cancer	4.74e-05	0.000352	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—breast cancer	4.71e-05	0.00035	CcSEcCtD
Pimecrolimus—Nervous system disorder—Docetaxel—breast cancer	4.69e-05	0.000349	CcSEcCtD
Pimecrolimus—Pruritus—Fluorouracil—breast cancer	4.69e-05	0.000349	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—breast cancer	4.68e-05	0.000348	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—breast cancer	4.68e-05	0.000348	CcSEcCtD
Pimecrolimus—Skin disorder—Docetaxel—breast cancer	4.65e-05	0.000345	CcSEcCtD
Pimecrolimus—Oedema—Capecitabine—breast cancer	4.63e-05	0.000344	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Paclitaxel—breast cancer	4.62e-05	0.000343	CcSEcCtD
Pimecrolimus—Diarrhoea—Gemcitabine—breast cancer	4.61e-05	0.000343	CcSEcCtD
Pimecrolimus—Infection—Capecitabine—breast cancer	4.6e-05	0.000342	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—breast cancer	4.55e-05	0.000339	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—breast cancer	4.55e-05	0.000338	CcSEcCtD
Pimecrolimus—Nervous system disorder—Capecitabine—breast cancer	4.54e-05	0.000338	CcSEcCtD
Pimecrolimus—Eye disorder—Methotrexate—breast cancer	4.54e-05	0.000337	CcSEcCtD
Pimecrolimus—Diarrhoea—Fluorouracil—breast cancer	4.54e-05	0.000337	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—breast cancer	4.51e-05	0.000335	CcSEcCtD
Pimecrolimus—Skin disorder—Capecitabine—breast cancer	4.5e-05	0.000334	CcSEcCtD
Pimecrolimus—Urticaria—Paclitaxel—breast cancer	4.48e-05	0.000333	CcSEcCtD
Pimecrolimus—Abdominal pain—Paclitaxel—breast cancer	4.46e-05	0.000332	CcSEcCtD
Pimecrolimus—Body temperature increased—Paclitaxel—breast cancer	4.46e-05	0.000332	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—breast cancer	4.42e-05	0.000328	CcSEcCtD
Pimecrolimus—Vomiting—Mitoxantrone—breast cancer	4.4e-05	0.000327	CcSEcCtD
Pimecrolimus—Vomiting—Irinotecan—breast cancer	4.4e-05	0.000327	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—breast cancer	4.39e-05	0.000327	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—breast cancer	4.38e-05	0.000326	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—breast cancer	4.37e-05	0.000325	CcSEcCtD
Pimecrolimus—Rash—Mitoxantrone—breast cancer	4.36e-05	0.000324	CcSEcCtD
Pimecrolimus—Rash—Irinotecan—breast cancer	4.36e-05	0.000324	CcSEcCtD
Pimecrolimus—Dermatitis—Irinotecan—breast cancer	4.36e-05	0.000324	CcSEcCtD
Pimecrolimus—Dermatitis—Mitoxantrone—breast cancer	4.36e-05	0.000324	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Docetaxel—breast cancer	4.36e-05	0.000324	CcSEcCtD
Pimecrolimus—Headache—Irinotecan—breast cancer	4.34e-05	0.000322	CcSEcCtD
Pimecrolimus—Headache—Mitoxantrone—breast cancer	4.34e-05	0.000322	CcSEcCtD
Pimecrolimus—Paraesthesia—Docetaxel—breast cancer	4.3e-05	0.000319	CcSEcCtD
Pimecrolimus—Vomiting—Gemcitabine—breast cancer	4.29e-05	0.000319	CcSEcCtD
Pimecrolimus—Dyspnoea—Docetaxel—breast cancer	4.27e-05	0.000317	CcSEcCtD
Pimecrolimus—Rash—Gemcitabine—breast cancer	4.25e-05	0.000316	CcSEcCtD
Pimecrolimus—Dermatitis—Gemcitabine—breast cancer	4.25e-05	0.000316	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—breast cancer	4.25e-05	0.000316	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—breast cancer	4.23e-05	0.000314	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—breast cancer	4.23e-05	0.000314	CcSEcCtD
Pimecrolimus—Headache—Gemcitabine—breast cancer	4.22e-05	0.000314	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Capecitabine—breast cancer	4.22e-05	0.000314	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—breast cancer	4.22e-05	0.000313	CcSEcCtD
Pimecrolimus—Vomiting—Fluorouracil—breast cancer	4.22e-05	0.000313	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—breast cancer	4.21e-05	0.000313	CcSEcCtD
Pimecrolimus—Rash—Fluorouracil—breast cancer	4.18e-05	0.000311	CcSEcCtD
Pimecrolimus—Dermatitis—Fluorouracil—breast cancer	4.18e-05	0.00031	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—breast cancer	4.17e-05	0.00031	CcSEcCtD
Pimecrolimus—Paraesthesia—Capecitabine—breast cancer	4.16e-05	0.000309	CcSEcCtD
Pimecrolimus—Hypersensitivity—Paclitaxel—breast cancer	4.16e-05	0.000309	CcSEcCtD
Pimecrolimus—Headache—Fluorouracil—breast cancer	4.15e-05	0.000309	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Docetaxel—breast cancer	4.13e-05	0.000307	CcSEcCtD
Pimecrolimus—Dyspnoea—Capecitabine—breast cancer	4.13e-05	0.000307	CcSEcCtD
Pimecrolimus—Nausea—Mitoxantrone—breast cancer	4.11e-05	0.000306	CcSEcCtD
Pimecrolimus—Nausea—Irinotecan—breast cancer	4.11e-05	0.000306	CcSEcCtD
Pimecrolimus—Immune system disorder—Epirubicin—breast cancer	4.1e-05	0.000305	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—breast cancer	4.09e-05	0.000304	CcSEcCtD
Pimecrolimus—Pain—Docetaxel—breast cancer	4.09e-05	0.000304	CcSEcCtD
Pimecrolimus—Constipation—Docetaxel—breast cancer	4.09e-05	0.000304	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—breast cancer	4.09e-05	0.000304	CcSEcCtD
Pimecrolimus—Nausea—Gemcitabine—breast cancer	4.01e-05	0.000298	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Capecitabine—breast cancer	4e-05	0.000297	CcSEcCtD
Pimecrolimus—Pruritus—Paclitaxel—breast cancer	3.99e-05	0.000297	CcSEcCtD
Pimecrolimus—Pain—Capecitabine—breast cancer	3.96e-05	0.000294	CcSEcCtD
Pimecrolimus—Constipation—Capecitabine—breast cancer	3.96e-05	0.000294	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—breast cancer	3.95e-05	0.000294	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—breast cancer	3.95e-05	0.000294	CcSEcCtD
Pimecrolimus—Nausea—Fluorouracil—breast cancer	3.94e-05	0.000293	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—breast cancer	3.93e-05	0.000292	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Docetaxel—breast cancer	3.91e-05	0.000291	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—breast cancer	3.9e-05	0.00029	CcSEcCtD
Pimecrolimus—Diarrhoea—Paclitaxel—breast cancer	3.86e-05	0.000287	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—breast cancer	3.83e-05	0.000284	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—breast cancer	3.8e-05	0.000282	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Capecitabine—breast cancer	3.79e-05	0.000282	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—breast cancer	3.79e-05	0.000282	CcSEcCtD
Pimecrolimus—Abdominal pain—Docetaxel—breast cancer	3.78e-05	0.000281	CcSEcCtD
Pimecrolimus—Body temperature increased—Docetaxel—breast cancer	3.78e-05	0.000281	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—breast cancer	3.69e-05	0.000274	CcSEcCtD
Pimecrolimus—Urticaria—Capecitabine—breast cancer	3.68e-05	0.000274	CcSEcCtD
Pimecrolimus—Body temperature increased—Capecitabine—breast cancer	3.66e-05	0.000272	CcSEcCtD
Pimecrolimus—Abdominal pain—Capecitabine—breast cancer	3.66e-05	0.000272	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—breast cancer	3.66e-05	0.000272	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—breast cancer	3.66e-05	0.000272	CcSEcCtD
Pimecrolimus—Arthralgia—Methotrexate—breast cancer	3.6e-05	0.000267	CcSEcCtD
Pimecrolimus—Vomiting—Paclitaxel—breast cancer	3.59e-05	0.000267	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.57e-05	0.000266	CcSEcCtD
Pimecrolimus—Rash—Paclitaxel—breast cancer	3.56e-05	0.000265	CcSEcCtD
Pimecrolimus—Dermatitis—Paclitaxel—breast cancer	3.56e-05	0.000264	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—breast cancer	3.54e-05	0.000263	CcSEcCtD
Pimecrolimus—Headache—Paclitaxel—breast cancer	3.54e-05	0.000263	CcSEcCtD
Pimecrolimus—Hypersensitivity—Docetaxel—breast cancer	3.53e-05	0.000262	CcSEcCtD
Pimecrolimus—Cough—Epirubicin—breast cancer	3.45e-05	0.000257	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methotrexate—breast cancer	3.45e-05	0.000256	CcSEcCtD
Pimecrolimus—Infection—Methotrexate—breast cancer	3.43e-05	0.000255	CcSEcCtD
Pimecrolimus—Hypersensitivity—Capecitabine—breast cancer	3.41e-05	0.000254	CcSEcCtD
Pimecrolimus—Pruritus—Docetaxel—breast cancer	3.39e-05	0.000252	CcSEcCtD
Pimecrolimus—Nervous system disorder—Methotrexate—breast cancer	3.38e-05	0.000251	CcSEcCtD
Pimecrolimus—Arthralgia—Epirubicin—breast cancer	3.37e-05	0.00025	CcSEcCtD
Pimecrolimus—Nausea—Paclitaxel—breast cancer	3.35e-05	0.000249	CcSEcCtD
Pimecrolimus—Skin disorder—Methotrexate—breast cancer	3.35e-05	0.000249	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.34e-05	0.000249	CcSEcCtD
Pimecrolimus—Pruritus—Capecitabine—breast cancer	3.28e-05	0.000244	CcSEcCtD
Pimecrolimus—Diarrhoea—Docetaxel—breast cancer	3.27e-05	0.000243	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—breast cancer	3.23e-05	0.00024	CcSEcCtD
Pimecrolimus—Oedema—Epirubicin—breast cancer	3.23e-05	0.00024	CcSEcCtD
Pimecrolimus—Infection—Epirubicin—breast cancer	3.21e-05	0.000238	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—breast cancer	3.19e-05	0.000237	CcSEcCtD
Pimecrolimus—Diarrhoea—Capecitabine—breast cancer	3.17e-05	0.000236	CcSEcCtD
Pimecrolimus—Nervous system disorder—Epirubicin—breast cancer	3.17e-05	0.000235	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—breast cancer	3.14e-05	0.000234	CcSEcCtD
Pimecrolimus—Skin disorder—Epirubicin—breast cancer	3.13e-05	0.000233	CcSEcCtD
Pimecrolimus—Arthralgia—Doxorubicin—breast cancer	3.12e-05	0.000232	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—breast cancer	3.1e-05	0.00023	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.09e-05	0.00023	CcSEcCtD
Pimecrolimus—Dyspnoea—Methotrexate—breast cancer	3.07e-05	0.000229	CcSEcCtD
Pimecrolimus—Vomiting—Docetaxel—breast cancer	3.04e-05	0.000226	CcSEcCtD
Pimecrolimus—Rash—Docetaxel—breast cancer	3.02e-05	0.000224	CcSEcCtD
Pimecrolimus—Dermatitis—Docetaxel—breast cancer	3.01e-05	0.000224	CcSEcCtD
Pimecrolimus—Headache—Docetaxel—breast cancer	3e-05	0.000223	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—breast cancer	2.99e-05	0.000222	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—breast cancer	2.99e-05	0.000222	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—breast cancer	2.98e-05	0.000221	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—breast cancer	2.97e-05	0.000221	CcSEcCtD
Pimecrolimus—Pain—Methotrexate—breast cancer	2.95e-05	0.000219	CcSEcCtD
Pimecrolimus—Vomiting—Capecitabine—breast cancer	2.95e-05	0.000219	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—breast cancer	2.94e-05	0.000219	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—breast cancer	2.93e-05	0.000218	CcSEcCtD
Pimecrolimus—Rash—Capecitabine—breast cancer	2.92e-05	0.000217	CcSEcCtD
Pimecrolimus—Dermatitis—Capecitabine—breast cancer	2.92e-05	0.000217	CcSEcCtD
Pimecrolimus—Headache—Capecitabine—breast cancer	2.9e-05	0.000216	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—breast cancer	2.9e-05	0.000216	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—breast cancer	2.9e-05	0.000215	CcSEcCtD
Pimecrolimus—Dyspnoea—Epirubicin—breast cancer	2.88e-05	0.000214	CcSEcCtD
Pimecrolimus—Nausea—Docetaxel—breast cancer	2.84e-05	0.000211	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—breast cancer	2.82e-05	0.00021	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—breast cancer	2.79e-05	0.000207	CcSEcCtD
Pimecrolimus—Constipation—Epirubicin—breast cancer	2.76e-05	0.000205	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—breast cancer	2.76e-05	0.000205	CcSEcCtD
Pimecrolimus—Nausea—Capecitabine—breast cancer	2.75e-05	0.000205	CcSEcCtD
Pimecrolimus—Urticaria—Methotrexate—breast cancer	2.74e-05	0.000204	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—breast cancer	2.73e-05	0.000203	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—breast cancer	2.73e-05	0.000203	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.72e-05	0.000202	CcSEcCtD
Pimecrolimus—Paraesthesia—Doxorubicin—breast cancer	2.68e-05	0.000199	CcSEcCtD
Pimecrolimus—Dyspnoea—Doxorubicin—breast cancer	2.66e-05	0.000198	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Epirubicin—breast cancer	2.64e-05	0.000196	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—breast cancer	2.58e-05	0.000192	CcSEcCtD
Pimecrolimus—Urticaria—Epirubicin—breast cancer	2.56e-05	0.000191	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—breast cancer	2.55e-05	0.00019	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—breast cancer	2.55e-05	0.00019	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—breast cancer	2.55e-05	0.00019	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—breast cancer	2.55e-05	0.00019	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methotrexate—breast cancer	2.54e-05	0.000189	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—breast cancer	2.44e-05	0.000182	CcSEcCtD
Pimecrolimus—Pruritus—Methotrexate—breast cancer	2.44e-05	0.000181	CcSEcCtD
Pimecrolimus—Hypersensitivity—Epirubicin—breast cancer	2.38e-05	0.000177	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—breast cancer	2.37e-05	0.000176	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—breast cancer	2.36e-05	0.000175	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—breast cancer	2.36e-05	0.000175	CcSEcCtD
Pimecrolimus—Diarrhoea—Methotrexate—breast cancer	2.36e-05	0.000175	CcSEcCtD
Pimecrolimus—Pruritus—Epirubicin—breast cancer	2.28e-05	0.00017	CcSEcCtD
Pimecrolimus—Diarrhoea—Epirubicin—breast cancer	2.21e-05	0.000164	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—breast cancer	2.2e-05	0.000164	CcSEcCtD
Pimecrolimus—Vomiting—Methotrexate—breast cancer	2.19e-05	0.000163	CcSEcCtD
Pimecrolimus—Rash—Methotrexate—breast cancer	2.17e-05	0.000162	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—breast cancer	2.17e-05	0.000161	CcSEcCtD
Pimecrolimus—Headache—Methotrexate—breast cancer	2.16e-05	0.000161	CcSEcCtD
Pimecrolimus—Pruritus—Doxorubicin—breast cancer	2.11e-05	0.000157	CcSEcCtD
Pimecrolimus—Vomiting—Epirubicin—breast cancer	2.05e-05	0.000153	CcSEcCtD
Pimecrolimus—Nausea—Methotrexate—breast cancer	2.05e-05	0.000152	CcSEcCtD
Pimecrolimus—Diarrhoea—Doxorubicin—breast cancer	2.04e-05	0.000152	CcSEcCtD
Pimecrolimus—Rash—Epirubicin—breast cancer	2.03e-05	0.000151	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—breast cancer	2.03e-05	0.000151	CcSEcCtD
Pimecrolimus—Headache—Epirubicin—breast cancer	2.02e-05	0.00015	CcSEcCtD
Pimecrolimus—Nausea—Epirubicin—breast cancer	1.92e-05	0.000142	CcSEcCtD
Pimecrolimus—Vomiting—Doxorubicin—breast cancer	1.9e-05	0.000141	CcSEcCtD
Pimecrolimus—Rash—Doxorubicin—breast cancer	1.88e-05	0.00014	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—breast cancer	1.88e-05	0.00014	CcSEcCtD
Pimecrolimus—Headache—Doxorubicin—breast cancer	1.87e-05	0.000139	CcSEcCtD
Pimecrolimus—Nausea—Doxorubicin—breast cancer	1.77e-05	0.000132	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—MMP3—breast cancer	5.91e-06	4.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB4—breast cancer	5.91e-06	4.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—breast cancer	5.9e-06	4.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KIT—breast cancer	5.89e-06	4.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APC—breast cancer	5.89e-06	4.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—breast cancer	5.87e-06	4.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT2—breast cancer	5.84e-06	4.73e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGF—breast cancer	5.82e-06	4.71e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MDM2—breast cancer	5.78e-06	4.68e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—breast cancer	5.76e-06	4.67e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RAF1—breast cancer	5.76e-06	4.66e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TGFB1—breast cancer	5.75e-06	4.66e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLCO1B1—breast cancer	5.73e-06	4.64e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A5—breast cancer	5.73e-06	4.64e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RELA—breast cancer	5.73e-06	4.64e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMAD4—breast cancer	5.72e-06	4.63e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—breast cancer	5.7e-06	4.61e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1R—breast cancer	5.69e-06	4.61e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—breast cancer	5.66e-06	4.58e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—breast cancer	5.64e-06	4.56e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MTOR—breast cancer	5.62e-06	4.55e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CB—breast cancer	5.62e-06	4.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CD—breast cancer	5.61e-06	4.54e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HES1—breast cancer	5.59e-06	4.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—breast cancer	5.57e-06	4.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PLA2G4A—breast cancer	5.56e-06	4.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NCOR1—breast cancer	5.56e-06	4.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BRAF—breast cancer	5.54e-06	4.48e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APRT—breast cancer	5.54e-06	4.48e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF1—breast cancer	5.49e-06	4.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CSF2—breast cancer	5.49e-06	4.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRG1—breast cancer	5.45e-06	4.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—H2AFX—breast cancer	5.41e-06	4.38e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—breast cancer	5.4e-06	4.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT2—breast cancer	5.39e-06	4.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—E2F1—breast cancer	5.38e-06	4.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—breast cancer	5.35e-06	4.33e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—breast cancer	5.33e-06	4.31e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1B—breast cancer	5.28e-06	4.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ANGPTL4—breast cancer	5.21e-06	4.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ESRRA—breast cancer	5.21e-06	4.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CD—breast cancer	5.18e-06	4.19e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—breast cancer	5.17e-06	4.19e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SPP1—breast cancer	5.17e-06	4.18e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—breast cancer	5.16e-06	4.18e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SERPINE1—breast cancer	5.12e-06	4.15e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—breast cancer	5.12e-06	4.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB3—breast cancer	5.11e-06	4.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR2—breast cancer	5.1e-06	4.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—breast cancer	5.1e-06	4.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—breast cancer	5.05e-06	4.09e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—breast cancer	5.03e-06	4.07e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MDM2—breast cancer	5.03e-06	4.07e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JUN—breast cancer	5.02e-06	4.07e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RAF1—breast cancer	5.01e-06	4.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RELA—breast cancer	4.99e-06	4.04e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNB1—breast cancer	4.98e-06	4.03e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—breast cancer	4.96e-06	4.01e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HADHB—breast cancer	4.94e-06	4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPI—breast cancer	4.94e-06	4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—breast cancer	4.91e-06	3.98e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—breast cancer	4.9e-06	3.96e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—breast cancer	4.89e-06	3.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—breast cancer	4.89e-06	3.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CB—breast cancer	4.89e-06	3.96e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—breast cancer	4.89e-06	3.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—breast cancer	4.88e-06	3.95e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1A—breast cancer	4.87e-06	3.94e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—breast cancer	4.86e-06	3.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR1—breast cancer	4.75e-06	3.85e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK8—breast cancer	4.75e-06	3.85e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—breast cancer	4.74e-06	3.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDH7A1—breast cancer	4.71e-06	3.81e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDH1A1—breast cancer	4.71e-06	3.81e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—breast cancer	4.68e-06	3.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MDM2—breast cancer	4.64e-06	3.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RAF1—breast cancer	4.62e-06	3.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1B—breast cancer	4.59e-06	3.71e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—breast cancer	4.57e-06	3.7e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—LEP—breast cancer	4.57e-06	3.7e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—breast cancer	4.55e-06	3.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—breast cancer	4.53e-06	3.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CAV1—breast cancer	4.53e-06	3.67e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—breast cancer	4.53e-06	3.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CB—breast cancer	4.51e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FHL2—breast cancer	4.51e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NME1—breast cancer	4.51e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UMPS—breast cancer	4.51e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PHGDH—breast cancer	4.51e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADSL—breast cancer	4.51e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—breast cancer	4.51e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—breast cancer	4.51e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SRC—breast cancer	4.5e-06	3.65e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—breast cancer	4.49e-06	3.64e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—breast cancer	4.48e-06	3.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—breast cancer	4.47e-06	3.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPSE—breast cancer	4.43e-06	3.58e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BRIP1—breast cancer	4.43e-06	3.58e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—LDHB—breast cancer	4.43e-06	3.58e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—breast cancer	4.39e-06	3.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—JUN—breast cancer	4.37e-06	3.54e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ESR1—breast cancer	4.36e-06	3.53e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—breast cancer	4.34e-06	3.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTNNB1—breast cancer	4.34e-06	3.51e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—breast cancer	4.33e-06	3.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FN1—breast cancer	4.31e-06	3.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NFKBIA—breast cancer	4.26e-06	3.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1B—breast cancer	4.24e-06	3.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1A—breast cancer	4.23e-06	3.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—breast cancer	4.23e-06	3.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH1—breast cancer	4.22e-06	3.42e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA3—breast cancer	4.2e-06	3.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMMR—breast cancer	4.2e-06	3.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCC1—breast cancer	4.2e-06	3.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—breast cancer	4.18e-06	3.38e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK3—breast cancer	4.15e-06	3.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK8—breast cancer	4.13e-06	3.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APC—breast cancer	4.13e-06	3.34e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—breast cancer	4.13e-06	3.34e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIT—breast cancer	4.13e-06	3.34e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGF—breast cancer	4.08e-06	3.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARGC1B—breast cancer	4.06e-06	3.29e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—breast cancer	4.04e-06	3.27e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TGFB1—breast cancer	4.03e-06	3.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—breast cancer	4.01e-06	3.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CTNNB1—breast cancer	4e-06	3.24e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—breast cancer	4e-06	3.24e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—breast cancer	3.95e-06	3.2e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SRC—breast cancer	3.92e-06	3.17e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1A—breast cancer	3.91e-06	3.17e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—breast cancer	3.9e-06	3.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BRAF—breast cancer	3.88e-06	3.14e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA4—breast cancer	3.84e-06	3.11e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CA9—breast cancer	3.84e-06	3.11e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—breast cancer	3.78e-06	3.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1—breast cancer	3.78e-06	3.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT2—breast cancer	3.77e-06	3.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX2—breast cancer	3.74e-06	3.03e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA2—breast cancer	3.74e-06	3.03e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—breast cancer	3.73e-06	3.02e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX4—breast cancer	3.7e-06	2.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SULT1A1—breast cancer	3.7e-06	2.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CD—breast cancer	3.63e-06	2.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SRC—breast cancer	3.62e-06	2.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK3—breast cancer	3.61e-06	2.92e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA1—breast cancer	3.61e-06	2.92e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—IDH1—breast cancer	3.61e-06	2.92e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SERPINE1—breast cancer	3.59e-06	2.9e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NAT2—breast cancer	3.57e-06	2.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—breast cancer	3.49e-06	2.82e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—breast cancer	3.43e-06	2.78e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—breast cancer	3.43e-06	2.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—breast cancer	3.43e-06	2.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK3—breast cancer	3.33e-06	2.7e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—breast cancer	3.32e-06	2.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MDM2—breast cancer	3.25e-06	2.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—breast cancer	3.24e-06	2.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—breast cancer	3.24e-06	2.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RAF1—breast cancer	3.24e-06	2.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TGFB1—breast cancer	3.23e-06	2.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RELA—breast cancer	3.22e-06	2.61e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—breast cancer	3.2e-06	2.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—breast cancer	3.17e-06	2.57e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—breast cancer	3.17e-06	2.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CB—breast cancer	3.16e-06	2.56e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MED12—breast cancer	3.13e-06	2.53e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—DPYD—breast cancer	3.13e-06	2.53e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDOA—breast cancer	3.08e-06	2.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—breast cancer	3.04e-06	2.46e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—breast cancer	3.03e-06	2.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—breast cancer	3e-06	2.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA3—breast cancer	2.99e-06	2.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—breast cancer	2.98e-06	2.41e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A2—breast cancer	2.97e-06	2.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1B—breast cancer	2.97e-06	2.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CPT1A—breast cancer	2.91e-06	2.36e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTR—breast cancer	2.91e-06	2.36e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCG2—breast cancer	2.91e-06	2.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—breast cancer	2.91e-06	2.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—breast cancer	2.9e-06	2.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPGDS—breast cancer	2.85e-06	2.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HBA1—breast cancer	2.84e-06	2.3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—breast cancer	2.83e-06	2.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JUN—breast cancer	2.82e-06	2.29e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNB1—breast cancer	2.8e-06	2.27e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—breast cancer	2.8e-06	2.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ACHE—breast cancer	2.77e-06	2.24e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTT1—breast cancer	2.77e-06	2.24e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—breast cancer	2.76e-06	2.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—breast cancer	2.75e-06	2.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—breast cancer	2.75e-06	2.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1A—breast cancer	2.74e-06	2.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—breast cancer	2.73e-06	2.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK8—breast cancer	2.67e-06	2.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—breast cancer	2.64e-06	2.14e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP17A1—breast cancer	2.62e-06	2.12e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO1—breast cancer	2.59e-06	2.1e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS1—breast cancer	2.59e-06	2.1e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—breast cancer	2.55e-06	2.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2D6—breast cancer	2.54e-06	2.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SRC—breast cancer	2.53e-06	2.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA2—breast cancer	2.5e-06	2.02e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—breast cancer	2.47e-06	2e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—breast cancer	2.44e-06	1.98e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—breast cancer	2.44e-06	1.97e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—breast cancer	2.44e-06	1.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FASN—breast cancer	2.42e-06	1.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BCHE—breast cancer	2.41e-06	1.95e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A5—breast cancer	2.38e-06	1.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK3—breast cancer	2.33e-06	1.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NQO1—breast cancer	2.3e-06	1.86e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A1—breast cancer	2.3e-06	1.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—breast cancer	2.27e-06	1.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TGFB1—breast cancer	2.26e-06	1.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—breast cancer	2.25e-06	1.82e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—breast cancer	2.22e-06	1.8e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1B1—breast cancer	2.2e-06	1.78e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.16e-06	1.75e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA1—breast cancer	2.1e-06	1.7e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—breast cancer	2.1e-06	1.7e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STK11—breast cancer	2.07e-06	1.68e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP19A1—breast cancer	2.07e-06	1.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—breast cancer	1.93e-06	1.56e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COMT—breast cancer	1.93e-06	1.56e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTP1—breast cancer	1.92e-06	1.55e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HMOX1—breast cancer	1.89e-06	1.53e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ITPR1—breast cancer	1.89e-06	1.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—breast cancer	1.86e-06	1.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCB1—breast cancer	1.82e-06	1.47e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMS—breast cancer	1.78e-06	1.44e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—breast cancer	1.78e-06	1.44e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—breast cancer	1.76e-06	1.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOR1—breast cancer	1.76e-06	1.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.76e-06	1.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—breast cancer	1.71e-06	1.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—breast cancer	1.69e-06	1.37e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1A1—breast cancer	1.67e-06	1.35e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ERCC2—breast cancer	1.66e-06	1.34e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—breast cancer	1.57e-06	1.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—breast cancer	1.56e-06	1.26e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAV1—breast cancer	1.44e-06	1.16e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—breast cancer	1.31e-06	1.06e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CD—breast cancer	1.15e-06	9.31e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—breast cancer	1.14e-06	9.19e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—breast cancer	1.09e-06	8.8e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CB—breast cancer	1e-06	8.12e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—breast cancer	9.94e-07	8.04e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—breast cancer	8.67e-07	7.02e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—breast cancer	6.11e-07	4.95e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—breast cancer	4.99e-07	4.04e-06	CbGpPWpGaD
